Section 4 of 6
Clinical evidence
152 evidence topics · 22 sources
Study summaries
X-TOLE
Objective
Trial objective: efficacy and safety of a KV7.2 and KV7.3 opener in focal onset seizures
Primary and secondary objectives stated by the investigators
“The primary objectives of X-TOLE were to assess the efficacy, safety, and tolerability of 3 doses of XEN1101 in comparison with placebo on FOS frequency in adults with focal epilepsy. Secondary objectives included an assessment of 50% responder rates and a characterization of the effects of each XEN1101 dose on seizure frequency in weekly intervals during the double-blind phase (DBP) to allow a determination of the speed of onset and durability of response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additional exploratory analyses reported herein include a time-to-event analysis (time for seizure count to reach the baseline monthly count) and an assessment of the effects of XEN1101 on overall health status as reported by the patients and their caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Summary: sites, countries, and enrollment period
The registry record for NCT03796962 lists 95 investigative sites in 9 countries: the United States (54 sites), Spain (15), Germany (9), Italy (7), the United Kingdom (4), Canada (3), Georgia (1), Moldova (1), and Ukraine (1). The registry gives an actual study start date of January 30, 2019, an actual primary completion date of September 2, 2021, and an estimated completion date of October 2028 for the continuing open-label extension. The primary publication reports 97 trial sites in North America and Europe, while the open-label extension publication reports 95 sites. The sponsor is Xenon Pharmaceuticals Inc., and the protocol identifier is XPF-008-201.
Number of sites and regions
“Adults experiencing 4 or more monthly FOSs while receiving stable treatment (1-3 ASMs) were enrolled at 97 sites in North America and Europe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were enrolled in North America (39.1%) or Europe (60.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Site count reported in the open-label extension publication
Study dates
“This phase 2b, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging adjunctive trial investigated XEN1101 over an 8-week treatment period from January 30, 2019, to September 2, 2021, and included a 6-week safety follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The present article reports findings from the completed DBP of the study, including the first patient randomized in June 2019 through the last patient treated in August 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Randomized, double-blind, placebo-controlled, dose-ranging adjunctive design
“This was a multicenter, randomized, double-blind, parallel-group, dose-ranging, placebo-controlled adjunctive-therapy clinical trial in which XEN1101 was administered once daily with food as a 10-, 20-, or 25-mg oral capsule.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients meeting eligibility criteria were randomized for an 8-week DBP to 1 of 3 active treatment groups or placebo in a 2:1:1:2 ratio: 25, 20, or 10 mg of XEN1101 or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline period and electronic seizure diary
“Key eligibility criteria included experiencing 4 or more countable FOSs on average per month, recorded from home in an e-diary during a prospective 8-week baseline period, while receiving stable treatment of between 1 and 3 ASMs. The e-diary stored daily seizure and treatment adherence information that was electronically transmitted to the database. Central surveillance of e-diary functionality and patient adherence, as well as clinical status, was used in addition to patient monitoring by participating sites.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Extensions of the baseline period up to 20 weeks were allowed if COVID-19 pandemic-related site access restrictions prevented patients from attending site visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Randomization method and stratification
“To ensure balanced distribution across groups, randomization was stratified by background use of CYP3A4 inducer medications (eg, carbamazepine, eslicarbazepine acetate, oxcarbazepine, phenytoin, topiramate, or phenobarbital). Randomization was implemented centrally in the Medidata Rave Randomization and Trial Supply Management system, using a dynamic allocation randomization algorithm (nondeterministic).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Follow-up and total study duration for participants not entering the extension
“Patients who did not participate in the open-label extension (OLE) had a follow-up visit 1 week posttreatment and a final follow-up visit 6 weeks following the last dose. The total study duration per randomized patient (for those not entering the OLE) was approximately 26 weeks (6 months) from screening to follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension design
“Participants who completed the DBP with a minimum of 80% study medication compliance and no important protocol deviations were eligible to enter the OLE phase, during which participants from all DBP arms began treatment with azetukalner 20 mg taken once daily with food (Figure 1). Azetukalner dose adjustments and changes in concomitant ASMs were allowed during the OLE. Assessments occurred at week 3 in the OLE (study day 77, week 11 from randomization) and at 3-month intervals thereafter for the first year. After the first year, on-site visits occurred at 6-month intervals, with teleconferences at 3 months between each on-site visit. The OLE phase is scheduled for completion after 378 weeks (7 years) of treatment, and no participant has yet completed the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Age range and countable seizure types
“Adults aged 18 to 75 years with FOSs provided written informed consent and were enrolled; participants did not receive financial compensation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The types of countable focal seizures assessed included focal aware seizures with motor signs, focal seizures with impaired awareness, and focal seizures evolving to bilateral tonic-clonic seizures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Seizure frequency and background antiseizure medication requirements
“Participants needed to be 18–75 years old with a diagnosis of focal epilepsy per International League Against Epilepsy criteria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“for ≥2 years, experience ≥4 countable FOS per month during an 8-week minimum baseline period, and receive stable treatment with 1–3 ASMs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key inclusion criteria as registered
Key exclusion criteria: seizure type and epilepsy syndrome
Key exclusion criteria: prior ezogabine, vigabatrin, and felbamate exposure
Key exclusion criteria: psychiatric, cardiac, and other medical conditions
Treatment
Dose groups, formulation, and administration with food
“Patients were randomized 2:1:1:2 to receive XEN1101, 25, 20, or 10 mg, or placebo with food once daily for 8 weeks. Dosage titration was not used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“XEN1101 was administered as a once-daily adjunctive treatment in capsule formulation by mouth. Because the oral bioavailability of XEN1101 is enhanced by coadministration with food, patients were instructed to take the study medication with the evening meal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic rationale for once-daily dosing without titration
“The pharmacokinetic properties of XEN1101, including a long terminal elimination half-life (approximately 10 days), support once-daily oral dosing without the need for titration at initiation of dosing or tapering at termination of dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concomitant antiseizure medications during the double-blind phase
“A total of 8.9% of the patients received 1 stable ASM at baseline and concomitantly throughout the DBP of the study, 40.6% of the patients received 2, and 50.5% of the patients received 3. Patients had tried and stopped a median of 6 previous ASMs before study entry. More than half of the patients (57.8%) were taking a CYP3A4 inducer at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Requirement for stable background medication
Study outcomes
Rationale for using median percent change in monthly focal onset seizure frequency as the primary endpoint
Primary endpoint and safety measures
“The primary efficacy end point was the median percent change from baseline in monthly FOS frequency. Treatment-emergent adverse events (TEAEs) were recorded and comprehensive laboratory assessments were made. Modified intention-to-treat analysis was conducted.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered secondary outcome measures
Safety assessments
“Safety was assessed as severity and frequency of treatment-emergent adverse events (TEAEs) and serious AEs, clinically significant changes in laboratory findings, and other measures including electrocardiography.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term outcome measures assessed in the open-label extension
“Long-term seizure outcomes included median percentage change (MPC) in monthly (28 days) FOS frequency from the double-blind phase (DBP) baseline and achievement of ≥50%, ≥75%, ≥90%, and 100% seizure reductions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term safety was assessed by frequency and severity of TEAEs and serious adverse events (SAEs). Additional safety outcomes included findings from physical, neurologic, and ophthalmoscopy examinations, clinically significant laboratory findings, vital signs, 12-lead electrocardiograph, and urological symptoms, as well as an increase in suicide risk via the Columbia-Suicide Severity Rating Scale.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose-response objective and analysis model
“The primary study objective was to assess the dose-response activity of XEN1101 in reducing monthly (28-day) FOS frequency, and the primary end point assessed the monotonic dose-response relationship between the XEN1101 active dose groups compared with placebo, based on a ranked analysis of covariance model.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The analysis of percent change from baseline was calculated based on monthly (28 days) FOS frequency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unmet need that the endpoint is intended to capture
“Many individuals with epilepsy continue to experience seizures despite treatment with available antiseizure medications (ASMs). There is therefore a need for more efficacious ASMs, and particularly for ones that confer greater seizure reduction or seizure freedom.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Responder rate as the accompanying secondary efficacy criterion
Statistical analysis description
Number of participants (Planned and analyzed)
Participants randomized and analyzed
“A total of 325 patients who were randomized and treated were included in the safety population (Figure 1B) and 323 patients in the modified intention-to-treat population were included in the efficacy analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 325 patients who were randomized and treated were included in the safety analysis; 285 completed the 8-week double-blind phase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants screened and randomized
Description of analysis sets
Modified intention-to-treat population used for efficacy
Statistical testing and estimation
“Both 1-sided and 2-sided tests are reported, with significance threshold set at P < .05. The Hodges-Lehmann estimate for each dose vs placebo was calculated accompanied by the associated 2-sided 90% and 95% CIs. Statistical analysis was conducted with SAS, version 9.4 or higher (SAS Institute Inc).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension analysis populations
“The MPC analysis was conducted for the overall group, for a numerically constant cohort group, which consisted of participants who were treated for at least 24 months in the OLE and for those who were continuing in the study at data cutoff.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Completion of the double-blind phase and entry into the open-label extension
Overall dropout during the double-blind phase
Discontinuation due to treatment-emergent adverse events by dose group
Open-label extension disposition at the 24-month interim analysis
“As of September 5, 2023 (cutoff date for the current interim analysis), 152 (55.3%) remained in the study, 182 (66%) had been treated in the OLE for ≥12 months, and 165 (60%) had been treated for ≥24 months. The mean and median duration of treatment were 662 days (21.8 months) and 799 days (26.3 months), respectively (range, 0.1–46.6 months). Of all participants who entered the OLE (N = 275), 67 participants (24.4%) had dose reductions. The most common reasons given for discontinuation were lack of efficacy (n = 38, 13.8%), AEs (n = 33, 12.0%), and study withdrawal by the participant (n = 33, 12.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension disposition at the April 2025 data cut
Baseline characteristics
Demographic characteristics of the randomized population
“Patient baseline demographic and other characteristics are presented in Table 1 and were generally comparable across groups at study entry. Mean (SD) patient age was 40.8 (13.3) years, 168 (51.7%) were female, and 298 (91.7%) identified their race as White.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) body mass index was 26.8 (5.2) (calculated as weight in kilograms divided by height in meters squared). Patient mean (SD) age at the time of disease onset was 17.1 (13.6) years, with a range from 0 to 61 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline seizure frequency and treatment history
“A total of 8.9% of the patients received 1 stable ASM at baseline and concomitantly throughout the DBP of the study, 40.6% of the patients received 2, and 50.5% of the patients received 3. Patients had tried and stopped a median of 6 previous ASMs before study entry. More than half of the patients (57.8%) were taking a CYP3A4 inducer at baseline. The median baseline FOS frequency was 13.5 (IQR, 7.9-30.3) per month.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics by treatment group
Baseline characteristics of the open-label extension population
| Characteristic | Open-label extension population (n = 275) |
|---|---|
| Age at study entry, mean (SD), years | “41.1 (13.3)”View highlighted excerpt for this quote |
| Female | “138 (50.2)”View highlighted excerpt for this quote |
| White | “250 (90.9)”View highlighted excerpt for this quote |
| Black | “11 (4.0)”View highlighted excerpt for this quote |
| Europe | “166 (60.4)”View highlighted excerpt for this quote |
| North America | “109 (39.6)”View highlighted excerpt for this quote |
| Age at epilepsy onset, mean (SD), years | “18.1 (13.8)”View highlighted excerpt for this quote |
| Baseline seizure rate per month, median (IQR) | “13.5 (7.9, 30.3)”View highlighted excerpt for this quote |
| Number of ASMs tried and discontinued before study entry, mean (SD) | “6.5 (3.7)”View highlighted excerpt for this quote |
| Background ASM use: 3 | “144 (52.4)”View highlighted excerpt for this quote |
| CYP3A4 inducer use, n (%) | “160 (58.2)”View highlighted excerpt for this quote |
Efficacy results
Primary endpoint: dose response and median percent reduction in monthly focal onset seizure frequency
“A robust dose response for seizure reduction was present (primary dose-response test: P < .001) (Table 2). There was a greater reduction in monthly FOS frequency from baseline during the treatment period for patients receiving XEN1101 compared with those receiving placebo, and the effect was statistically significant for each dose. The median percent reduction and associated 2-sided P values from baseline in monthly FOS frequency was 52.8% (P < .001 vs placebo; IQR, −80.4% to −16.9%) in the 25-mg group, 46.4% (P < .001 vs placebo; IQR, −76.7% to −14.0%) in the 20-mg group, and 33.2% (P = .04 vs placebo; IQR, −61.8% to 0.0%) in the 10-mg group, compared with 18.2% (IQR, −37.3% to 7.0%) in the placebo group (Table 2 and Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy of azetukalner in the double-blind phase
Responder rates and seizure freedom during the double-blind phase
“Responders were defined as those who achieved a 50% or greater reduction from baseline in monthly FOS frequency. There was a dose-dependent increase in the number of responders (Figure 2B). The percentage and associated 2-sided P values vs placebo of patients who were responders was 54.5% (P < .001 vs placebo) in the 25-mg group, 43.1% (P < .001 vs placebo) in the 20-mg group, and 28.3% (P = .04 vs placebo) in the 10-mg group, compared with 14.9% in the placebo group (Figure 2B). Seizure freedom rates, derived from the median percent change at 100% reduction during the 8-week treatment period, in all observed patients were 6.3% in the 25-mg group, 7.8% in the 20-mg group, 2.2% in the 10-mg group, and 1.8% in the placebo group. In the completers, the rates of seizure freedom were 4.5% in the 25-mg group, 3.9% in the 20-mg group, 2.2% in the 10-mg group, and 1.8% in the placebo group (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor-reported primary and responder analyses
Onset of response at week 1
“The onset of response was rapid as assessed by post hoc analysis of the percentage of patients who were responders at the end of the first week. The percentages were 53.6% (P < .001 vs placebo) in the 25-mg group, 47.1% (P < .05 vs placebo) in the 20-mg group, and 43.5% (P < .05 vs placebo) in the 10-mg group, compared with 28.1% of patients receiving placebo. Analysis of the reductions in median weekly FOS frequencies at the end of the first week also demonstrated rapid onset: there was a reduction of 55.4% (P < .001 vs placebo) in the 25-mg group, 41.5% (P = .04 vs placebo) in the 20-mg group, and 39.1% (P < .01 vs placebo) in the 10-mg group, compared with 20.2% in the placebo group. The response in the 20- and 25-mg groups was sustained throughout the study (Figure 2D).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Post hoc week 1 analysis presented at a congress
Exploratory endpoint: time to reach baseline monthly seizure count
“The exploratory end point of time to reach baseline monthly FOS count was also assessed (Figure 2E). Patients in the placebo group reached their baseline monthly FOS count by a median of 4.7 weeks, whereas patients in the 10-mg XEN1101 group did not reach their monthly baseline FOS count until approximately week 6, and those in the 20-mg group until a median of 7.4 weeks. The median time to baseline FOS count was more than 8 weeks in the 25-mg group, because most patients did not reach this end point at the end of the 8-week treatment period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension: median percent change in monthly focal onset seizure frequency
“For ongoing OLE participants, monthly MPC reductions from the DBP baseline in FOS frequency improved over time from 61% (n = 266) at month 1, with MPC reductions (lower, upper quartile) from baseline of 68.5% (95.4, 37.0) at 3 months and 73.1% (100, 40.7) at 6 months (Figure 2A). At months 12, 18, and 24, the MPC reductions were 80.2% (100.0, 60.0), 83.0% (100, 50.9), and 83.2% (100, 53.2), respectively. For the constant cohort (treatment ≥24 months), the reductions in monthly MPC from baseline were 73.8% (100.0, 47.1) at 3 months and 78.8% (100.0, 49.2) at 6 months (Figure 2B). At months 12, 18, and 24, the constant cohort reductions were 82.1% (100.0, 62.8), 83.0% (100, 51.4) and 83.3% (100.0, 53.6), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension: responder rates and seizure freedom at 24 months
“In the OLE, 155 (56.4%) and 122 (44.4%) participants achieved a ≥50% seizure reduction for any consecutive ≥6-and ≥12-month period, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seizure reductions of ≥90% were achieved by 78 (28.4%) participants for any consecutive ≥6-month period and 54 (19.6%) participants for any consecutive ≥12-month period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“a ≥50% seizure reduction was achieved by 138 participants (83.6%) for any consecutive ≥6-month period and 115 (69.7%) participants for any consecutive ≥12-month period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seizure reductions of ≥90% for this population were achieved by 72 (43.6%) participants for any consecutive ≥6-month period and 52 (31.5%) participants for any consecutive ≥12-month period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seizure freedom (100% reduction in monthly FOS frequency) in the overall population was achieved by 61 (22.2%) and 41 (14.9%) participants for any consecutive ≥6-month period and ≥12-month period, respectively (Figure 3C). For participants who had been treated for ≥24 months in the OLE, seizure freedom was achieved by 57 (34.5%) participants for any consecutive ≥6-month period and 39 (23.6%) participants for any consecutive ≥12-month period. In ongoing participants (n = 152), 19.1% (29/152) experienced seizure freedom for ≥12 months since the last visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension: summary of long-term efficacy
“Azetukalner 20 mg once-daily with food yielded long-term efficacy in this open-label extension (OLE) study with 60% retention at 24 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sustained monthly reduction in seizure frequency (median percentage change 80.2%–83.2%) from baseline was observed during OLE months 12–24.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seizure freedom for ≥6- and ≥12-month consecutive durations was achieved in 22.2% and 14.9% of OLE participants, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seizure freedom for ≥6- and ≥12-month consecutive durations was achieved in 34.5% and 23.6% of those treated for ≥24 months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension: 36-month interim results
Open-label extension: 42-month interim analysis
Open-label extension: 48-month interim analysis
Open-label extension: regaining seizure freedom after a breakthrough seizure
Health-related quality of life and patient-reported outcomes
Clinical and patient global impression of change during the double-blind phase
“The significant reductions in FOS frequency in patients receiving XEN1101 were associated with improvement in overall health status as assessed by both investigators, using the Clinical Global Impression–Change (CGI-C) scale, and by patients, using the Patient Global Impression–Change (PGI-C) scale. The difference in the percentage of patients who were much improved or very much improved between the placebo vs the 25-mg XEN1101 treatment groups was statistically significant for both the CGI-C (46.4% vs 22.8%; P < .001) and PGI-C (42.9% vs 21.9%; P = .001) (Table 2). In addition, the PGI-C results for the 20-mg dose, although underpowered, were statistically significant (37.3% vs 21.9%; P = .04), and numeric improvements over placebo were noted in the CGI-C for the 20-mg dose and the CGI-C and PGI-C for the 10-mg dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of Life in Epilepsy Inventory outcomes in the open-label extension at 1.5 years
Quality of life domains improving in the open-label extension at 2 years
Safety results
Overall tolerability and most common treatment-emergent adverse events
“The TEAEs are summarized in Table 3. XEN1101 was generally well tolerated in this study, with TEAEs being consistent with other commonly prescribed ASMs. The most common (>10%) TEAEs across all XEN1101 dose groups were dizziness (24.6%), somnolence (15.6%), and fatigue (10.9%). The incidence of TEAEs appeared to be dose related (Table 3). Weight increase as a TEAE was reported in 1 patient (0.9%) receiving placebo, 1 patient (2.2%) at 10 mg, 2 patients (3.9%) at 20 mg, and 3 patients (2.6%) at 25 mg. No TEAEs of tissue discoloration were reported. Two nonserious TEAEs of urinary retention were reported in the active treatment groups, 1 of which required a dose reduction; both patients continued to receive the study medication with no other changes or interventions, including no need for catheterization. The adverse event of confusional state was reported in 4.7% of the treated groups (2.2% receiving 10 mg, 5.9% receiving 20 mg, and 5.3% receiving 25 mg) and in 0.9% of the placebo group. No allergic rashes occurred.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Summary of adverse events in the double-blind phase
Discontinuations, serious adverse events, and deaths
“Discontinuation associated with TEAEs occurred in 3.5% of patients receiving placebo, 2.2% of patients receiving 10 mg, 13.7% of patients receiving 20 mg, and 15.8% of patients receiving 25 mg. The most common TEAEs leading to discontinuation across XEN1101 groups were dizziness (4.7%), balance disorder (2.4%), dysarthria (1.9%), and gait disturbance (1.9%). The incidence of serious AEs was low and balanced across treatment groups, occurring in 4.3% of patients receiving 10 mg, 3.9% of patients receiving 20 mg, and 2.6% of patients receiving 25 mg. The incidence of serious AEs in patients receiving placebo (2.6%) was the same as that recorded at the highest dose of XEN1101. There were no deaths in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular, laboratory, and body weight findings
“There were no cardiovascular signals of concern based on vital signs including orthostatic tests, and no safety signals of concern from physical or neurologic examinations. Mean (SD) body weight changes from baseline were 0.2 (2.4) kg in patients receiving placebo, 0.6 (2.3) kg in patients receiving 10 mg, 1.6 (2.2) kg in patients receiving 20 mg, and 1.9 (2.9) kg in patients receiving 25 mg. There were no signals of concern from electrocardiograms, laboratory tests evaluating safety, or urinalysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Absence of pigmentary abnormalities reported by the sponsor
Open-label extension: treatment-emergent adverse events at the 24-month interim analysis
“During the OLE, TEAEs were reported in 240 of 275 participants (87.3%) of the safety population (Table 2). Those reported most commonly (>10% of participants) were dizziness (21.8%), headache (15.3%), coronavirus infection (15.3%), somnolence (12.7%), fall (12.7%), and memory impairment (10.9%). Three participants reported urinary retention, 1 reported it as mild and 2 as moderate; no dose changes were made in any case. TEAEs that led to permanent treatment discontinuation (>2 participants) were dizziness (6 participants, 2.2%), somnolence (4 participants, 1.5%), and amnesia (3 participants, 1.1%). SAEs were reported in 35 participants (12.7%); SAEs reported in >1 participant were change in seizure presentation, reported in 6 participants (2.2%), and paresthesia, seizure, pneumonia aspiration, deep vein thrombosis, and fall, each reported in 2 participants (0.7%). There was 1 sudden unexpected death in epilepsy (SUDEP) reported, which was determined not to be related to the study drug. No signals of cardiovascular safety were identified as of the Sept 5, 2023, cutoff date. Overall, TEAEs were similar to those reported in the DBP, and no new safety signals were identified. At the end of the second year, participants recorded a mean (SD) weight change of −0.2 (8.8) kg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-emergent adverse events during the open-label extension
Long-term tolerability conclusions from the extension
“Safety results from the OLE demonstrate that azetukalner is generally well tolerated during long-term treatment, with a tolerability profile consistent with that reported during the DBP. Besides coronavirus infection and falls, the most commonly reported TEAEs were related to the central nervous system (dizziness, headache, somnolence, and memory impairment). One case of SUDEP has been reported, which was not attributed to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 10.9% of participants discontinued the OLE due to a TEAE. No new safety signals were observed, and no signals of cardiovascular safety were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cumulative exposure accrued in the open-label extension
Study limitations
Summary: limitations of the double-blind phase
The double-blind phase lasted 8 weeks, which the investigators identify as a limitation for assessing long-term safety and efficacy. Group sizes were unequal by design under the 2:1:1:2 randomization ratio, so the 10 mg group (n = 46) and 20 mg group (n = 51) were smaller than the placebo and 25 mg groups (n = 114 each), and the investigators note that the 20 mg analysis of global impression of change was underpowered. The investigators state that the effect of the COVID-19 pandemic on study outcomes is unknown and that pandemic restrictions on site access may have contributed to enrollment of a more refractory population, characterized by a median of 13.5 seizures per month and a median of 6 previously stopped antiseizure medications. Race was recorded but 298 of 325 participants (91.7%) identified as White, with less than 4% representation in any other category, so the investigators state that analysis by race would not contribute to a meaningful analysis in this single study. Seizure freedom rates derived from the 8-week treatment period were low in absolute terms, at 6.3% for 25 mg, 7.8% for 20 mg, 2.2% for 10 mg, and 1.8% for placebo among all observed participants.
Summary: limitations of the open-label extension
The open-label extension has no control group and no blinding, and the investigators note potential selection bias because not all participants who enrolled in the double-blind phase entered the extension, although 275 of 285 completers (96.5%) did so. Long-term efficacy estimates can be biased by dropout, because participants who perceive benefit may preferentially remain on treatment; retention was 60% at 24 months, with 13.8% discontinuing for lack of efficacy and 12.0% for adverse events. The investigators report that a constant-cohort analysis restricted to participants treated for at least 24 months produced comparable improvements, indicating that the improvement is not solely attributable to attrition bias. Comparisons against extension studies of other antiseizure medications are limited by differing methods and treatment durations. The data are interim: the extension is scheduled to run 378 weeks, or 7 years, and no participant had completed it at the time of the publication.
Limitations stated by the investigators for the double-blind phase
“Study limitations include the relatively short 8-week treatment duration; however, analysis of participants in the ongoing open-label extension phase is expected to provide insight into the long-term safety and efficacy of XEN1101. There were fewer individuals in the 10- and 20-mg groups compared with the placebo and 25-mg groups; nevertheless, a clear dose response was demonstrated. It is unknown what the impact of COVID-19 was on study outcomes. It is possible that general pandemic restrictions on site access may have contributed to enrollment of a more refractory population (ie, medians of 13.5 seizures/month and 6 previously stopped ASMs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitation on analysis by race
“The US Food and Drug Administration expects race to be collected as a covariate across the development program. With less than 4% representation in any other race category, analysis by race would not contribute to a meaningful analysis in this single study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations stated by the investigators for the open-label extension
“OLE trials, such as this study, have inherent limitations that must be considered when interpreting the results. Key limitations are the open-label design and lack of a control group. In addition, there could also be selection biases since not all participants who enrolled in the DBP entered the OLE phase. This limitation is mitigated in the present situation by the fact that nearly all eligible subjects chose to receive double-blind treatment, and almost all (96%) of those completing the DBP continued into the OLE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As in all OLE studies, long-term assessment can be biased by participant dropout during the course of the OLE. Participants who perceive that they are doing well may preferentially remain on treatment. Moreover, at 24 months in the OLE, retention on azetukalner remained high at 60%, with only 13.8% and 12.0% of participants discontinuing the study due to lack of efficacy and due to AEs, respectively. In addition, our analysis of efficacy outcomes in a constant cohort group shows comparable improvements, indicating that the improvement is not solely due to attrition bias.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitation of cross-study comparison of seizure freedom rates
X-TOLE2
Objective
Trial objective: adjunctive azetukalner in focal onset seizures
Location and study date
Summary: sponsor, identifiers, sites, and study dates
The registry record for NCT05614063 gives Xenon Pharmaceuticals Inc. as lead sponsor, Worldwide Clinical Trials as collaborator, and XPF-010-301 as the sponsor protocol number. The actual study start date was 18 November 2022, the actual primary completion date was 12 January 2026, and the actual study completion date was 3 February 2026. The record lists 125 study locations across 18 countries: the United States (56 sites), Spain (10), Australia (9), Argentina (8), Germany (8), the United Kingdom (7), Italy (4), Poland (4), Canada (3), Portugal (3), Chile (2), Georgia (2), Latvia (2), Mexico (2), New Zealand (2), Bulgaria (1), Czechia (1), and Ireland (1).
Study design
Randomization, baseline period, and double-blind period
Design as described by the sponsor at congress presentation
Design shared with the second Phase 3 focal seizure study
Eligibility criteria
Summary: age and sex eligibility
The registry record sets a minimum age of 18 years, accepts participants of all sexes, and does not accept healthy volunteers.
Exclusion criteria
Treatment
Summary: study arms and interventions
Participants were randomized in a 1:1:1 ratio to azetukalner 25 mg per day, azetukalner 15 mg per day, or placebo. The investigational product is recorded in the registry as XEN1101 capsules, with azetukalner given as the other name, and the comparator as placebo capsules.
Administration once daily with an evening meal
Study outcomes
Rationale for using median percent change in monthly focal onset seizure frequency as the primary endpoint
Summary: rationale for the primary endpoint
Median percent change in monthly seizure frequency from baseline through the 12-week double-blind period is the primary efficacy endpoint used across the Phase 3 epilepsy trials of azetukalner. The same measure was the primary endpoint of the Phase 2b X-TOLE trial, which allows the placebo-adjusted effect sizes of the two focal seizure trials supporting the New Drug Application to be compared directly.
Secondary outcome measures
Primary efficacy endpoint definition used across the Phase 3 epilepsy trials
Statistical analysis description
Number of participants (Planned and analyzed)
Participants randomized and analyzed
Participants analyzed per treatment group
| Treatment group | Quoted record |
|---|---|
| Azetukalner 25 mg | “Azetukalner 25 mg (n=124)” |
| Azetukalner 15 mg | “Azetukalner 15 mg (n=125)” |
| Placebo | “Placebo (n=125)” |
Description of analysis sets
Safety and modified intention-to-treat populations
Results
Participant disposition
Completion of the double-blind period and entry into the open-label extension
Discontinuation due to treatment-emergent adverse events
Baseline characteristics
Treatment resistance, seizure burden, and concomitant antiseizure medications
Prior and concomitant cenobamate use
Efficacy results
Primary endpoint: median percent change in monthly focal onset seizure frequency
Primary and key secondary endpoint results by treatment group
| Endpoint | Azetukalner 25 mg (n=124) | Azetukalner 15 mg (n=125) | Placebo (n=125) |
|---|---|---|---|
| Median percent change in monthly focal onset seizure frequency, baseline to week 12 | “-53.2% (p=0.000000000006)” | “-34.5% (p=0.00007)” | “-10.4%” |
| Proportion with at least a 50 percent reduction in monthly focal onset seizure frequency | “54.8%” | “37.6%” | “20.8%” |
Placebo-adjusted effect compared with the Phase 2b trial
Onset of effect at week 1 and dose-dependent responder rates
Seizure freedom over the double-blind period
Investigator characterization of the magnitude of effect
Health-related quality of life and patient-reported outcomes
Patient Global Impression of Change as a prespecified secondary endpoint
Reported patient-reported outcome results
No evidence found.
Safety results
Most common treatment-emergent adverse events
Adverse events of special interest not observed during the double-blind period
Consistency with the Phase 2b safety profile
Cumulative exposure across the epilepsy trials
Study limitations
Summary: limitations of the available X-TOLE2 evidence
As of September 2026, X-TOLE2 results are available only from company press releases and congress presentations. No peer-reviewed publication and no ClinicalTrials.gov results record have been posted, so treatment-group-level baseline characteristics, confidence intervals, the statistical testing hierarchy, and full adverse event tables are not publicly available. The double-blind period was 12 weeks, so durability of effect beyond that interval is inferred from a separate open-label extension rather than from randomized comparison. Enrollment was restricted to adults aged 18 years and older with focal epilepsy of at least 2 years duration who had failed at least 2 prior antiseizure medications and were taking 1 to 3 concomitant antiseizure medications, which limits generalizability to monotherapy use, to adolescents and children, and to newly diagnosed epilepsy. The reported analyses of the 100% responder rate over the last 8, 6, and 4 weeks of the double-blind period were post hoc and used nominal p-values. Patient Global Impression of Change was a prespecified secondary endpoint, but no results have been disclosed. Exact p-values differ between company statements, with the March 2026 topline release reporting p=0.000000000006 and p=0.00007 and the April 2026 congress release reporting p<0.0001 for both doses.
X-TOLE3
Objective
Trial objective: second Phase 3 trial of adjunctive azetukalner in focal onset seizures
Regulatory purpose stated by the sponsor
Location and study date
Summary: sponsor, identifiers, sites, and study dates
The registry record for NCT05716100 gives Xenon Pharmaceuticals Inc. as lead sponsor and XPF-010-302 as the sponsor protocol number, with an overall status of recruiting. The actual study start date was 9 May 2023, with estimated primary completion in October 2026 and estimated study completion in December 2026. The record lists 95 study locations across 20 countries: the United States (19 sites), Argentina (12), Portugal (8), Australia (6), France (6), Croatia (5), Poland (5), Chile (4), Israel (4), Mexico (4), Spain (4), Austria (3), Czechia (3), Germany (3), Belgium (2), Bulgaria (2), Italy (2), Finland (1), Hungary (1), and the Netherlands (1).
Study design
Randomization, baseline period, and double-blind period
Design shared with X-TOLE2 as described by the sponsor
Eligibility criteria
Exclusion criteria
Treatment
Summary: study arms and interventions
Participants are randomized in a 1:1:1 ratio to azetukalner 25 mg per day, azetukalner 15 mg per day, or placebo. The registry records the investigational product as XEN1101 capsules, with azetukalner given as the other name, and the comparator as placebo capsules.
Study outcomes
Rationale for using median percent change in monthly focal onset seizure frequency as the primary endpoint
Secondary outcome measures
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
Patient Global Impression of Change as a prespecified secondary endpoint
Safety results
No evidence found.
Study limitations
Summary: status of the X-TOLE3 evidence
X-TOLE3 is ongoing and recruiting, with estimated primary completion in October 2026 and estimated study completion in December 2026. No efficacy, safety, disposition, or baseline data have been reported. The trial is intended to support regulatory submissions outside the United States rather than the United States New Drug Application, which was submitted on the basis of X-TOLE and X-TOLE2. Enrollment outside Japan is expected to complete in 2026, which implies that Japanese enrollment continues beyond that date and that the full dataset will read out later than the primary completion estimate.
X-TOLE4
Objective
Location and study date
Summary: identifiers, dates, and enrollment
The registry record for NCT05718817 gives XPF-010-304 as the sponsor protocol number and X-TOLE4 as the acronym, with an overall status of enrolling by invitation. The actual study start date was 25 April 2023, with estimated primary completion in April 2033 and estimated study completion in June 2033. Estimated enrollment is 880 participants, with a minimum age of 12 years.
Study design
Eligibility criteria
Eligibility limited to completers of the antecedent Phase 3 studies
Treatment
Dosing and seizure diary compliance
Study outcomes
Rationale for using percent change in monthly seizure rate as a secondary endpoint
Outcome measures in the extension
Statistical analysis description
Number of participants (Planned and analyzed)
Summary: planned enrollment
The registry record gives an estimated enrollment of 880 participants drawn from the completers of X-TOLE2, X-TOLE3, and X-ACKT. Of the 332 participants who completed the X-TOLE2 double-blind period, 322 entered the open-label extension study.
Description of analysis sets
No evidence found.
Results
Participant disposition
Entry from the X-TOLE2 double-blind period
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
Quality of Life in Epilepsy Inventory as a prespecified outcome measure
Safety results
No evidence found.
Study limitations
Summary: status of the X-TOLE4 evidence
X-TOLE4 is an open-label extension with no control group and no blinding, enrolling by invitation from the completers of X-TOLE2, X-TOLE3, and X-ACKT. Estimated primary completion is April 2033, and no efficacy, safety, disposition, or baseline data have been reported. Because participants from three antecedent trials with two different seizure types are pooled, outcomes reported from this study will not be specific to focal onset seizures unless reported separately by antecedent trial.